Zinc Deficiency Treatment in Celiac Disease: Supplementation Versus Diet

Celiac Disease Clinical Trial

Official title:

A Pilot Study to Evaluate the Feasibility of a Zinc-optimized Gluten-free Diet Compared With Supplements to Treat Zinc Deficiency in Celiac Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05782257
• Other study ID #: 14999
• Status: Recruiting
• Phase: N/A
• Start date: December 8, 2022
• Est. completion date: September 1, 2024

Study information

• Verified date: March 2023
• Source: McMaster University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Micronutrient deficiencies are common amongst celiac disease (CeD) patients due to consumption of a restrictive and nutritionally unbalanced gluten-free diet (GFD) in addition to slow intestinal villi healing. Preliminary data of 221 patients attending our Celiac Disease Clinic at McMaster University show that 64% of patients on a GFD have nutrient deficiencies with zinc (Zn) deficiency affecting 48% of treated CeD patients. Dietary supplements are prescribed to treat Zn deficiency and it is unclear whether Zn levels can be restored with optimizing Zn in diet. This project will evaluate the the feasibility of dietary therapy to treat Zn deficiency in CeD in comparison to supplementation. Additional objectives of this pilot study, are to assess the efficacy of Zn optimized GFD compared to Zn supplements in 1) normalizing plasma Zn levels and 2) improving CeD gastrointestinal and extra-intestinal symptoms at 3 and 6 month. Subjects will be recruited from McMaster Celiac clinic. This randomized controlled trial aims to recruit 50 CeD participants with two treatment groups; zinc optimized diet (guided by dietitian to achieve target of 11 mg/day for females and 14 mg /day for males) or zinc oral supplementation (25 mg zinc gluconate tablet/day; 7 mg elemental Zn) with a total study a total study period of 6 months and 4 visits. To be included in the study the investigators require celiac diagnosed patients confirmed through CeD serology and duodenal biopsies adhering to a GFD > 6 months and plasma Zn ≤9.3 µmol/L. Questionnaires will be used to assess presentation of symptoms, dietary adherence, quality of life, depression and anxiety. The trial would be considered to be feasible if the enrolment fraction (i.e., number of enrolled patients /number of eligible patients) is 60% or above.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: September 1, 2024
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of CeD based on specific CeD serology (elevated anti-tissue transglutaminase IgA, deaminated gliadin peptides-Immunoglobulin G or anti-endomysial antibodies IgA) and confirmed by duodenal biopsies showing villous atrophy (Marsh 3a or greater);

• Adopting a gluten-free diet for at least 6 months;

• Untreated Zn deficiency (Zn plasma levels =9.3 µmol/L)

Exclusion Criteria:

• Are already on a Zn optimized diet;

• Treatment with Zn supplements or multivitamins containing >11 mg of Zn in the last month;

• Prior allergic reaction to Zn supplements;

• Treatment with antibiotics or probiotics supplements in the last 30 days;

• Pregnancy or lactation

• Current infection in the last 30 days;

• Intestinal obstruction, short gut (remnant bowel <180 cm), or any serious illness considered by the investigator that will interfere with the study procedure or results. Data including medication and supplementation will be recorded in case report form and Zn content added to total Zn in the analysis.

• Untreated pancreatic insufficiency (fecal elastase <200).

Related Conditions & MeSH terms

• Celiac Disease
• Nutrient Deficiency

Intervention

Dietary Supplement:
• Zinc Supplementation
Take one 25mg Zn gluconate tablet daily

Other:
• Zn-Optimized Diet
Consume 11 mg/day of zinc-rich foods for females and 14 mg/day in males.

Locations

Country	Name	City	State
Canada	McMaster University	Hamilton

Sponsors (2)

Lead Sponsor	Collaborator
McMaster University	Hamilton Health Sciences Corporation

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compliance of Dietary Therapy	To assess compliance to a zinc-optimized dietary treatment. Dietary compliance is measured through evaluating zinc levels from biweekly participant food diaries.	6 months
Primary	Compliance of Supplementation Therapy	To assess compliance to zinc supplementation therapy. Supplementation compliance is measured by pill counting.	6 months
Secondary	Change from Baseline in Zinc Plasma Levels at Month 3	Plasma Zinc will be measured through bloodwork. Normal plasma zinc (pZn) levels: 9.4 = pZn = 15 ug/dL. Change = (Month 3 - Baseline)	Baseline and Month 3
Secondary	Change in Zinc Plasma Levels from Month 3 to Month 6	Plasma Zinc will be measured through bloodwork. Normal plasma zinc (pZn) levels: 9.4 = pZn = 15 ug/dL. Change = (Month 6- Month 3)	Month 3 and Month 6
Secondary	Change from Baseline in Celiac Disease Symptoms at Month 3	The Celiac Symptoms Index (CSI) is a validated disease-specific symptom index in adults with celiac disease. Possible total scores range from 16 (no symptoms) to 80 (worst possible symptoms). Higher scores indicate increase in severity of symptoms. Change = (Month 3 - baseline)	Baseline and Month 3
Secondary	Change in Celiac Disease Symptoms from Month 3 to Month 6	The Celiac Symptoms Index (CSI) is a validated disease-specific symptom index in adults with celiac disease. Higher scores indicate increase in severity of symptoms. Possible total scores range from 16 (no symptoms) to 80 (worst possible symptoms). Change = (Month 6 - Month 3)	Month 3 and Month 6
Secondary	Change from Baseline in Extra-Intestinal Symptoms at Month 3	The Visual Analog Scale (VAS) is a validated subjective measure of acute and chronic pain.; Possible total scores range from 0 (no symptoms) to 100 (very severe symptoms). Higher scores indicate increase in severity of symptoms. Change = (Month 3 - Baseline).	Baseline and Month 3
Secondary	Change in Extra-Intestinal Symptoms from Month 3 to Month 6	The Visual Analog Scale (VAS) is a validated subjective measure of acute and chronic pain.; Possible total scores range from 0 (no symptoms) to 100 (very severe symptoms). Higher scores indicate increase in severity of depression and anxiety. Change = (Month 6 - Month 3).	Month 3 and Month 6
Secondary	Change from Baseline in Depression and Anxiety Symptoms at Month 3	The Hospital Anxiety and Depression Scale (HADS) is a questionnaire assessing patient anxiety and depression. Possible scores range from 0 (normal) to 21 (abnormal). Higher scores indicate increase in severity of depression and anxiety. Change = (Month 3- Baseline).	Baseline and Month 3
Secondary	Change in Depression and Anxiety Symptoms from Month 3 to Month 6	The Hospital Anxiety and Depression Scale (HADS) is a questionnaire assessing patient anxiety and depression. Possible scores range from 0 (normal) to 21 (abnormal). Higher scores indicate increase in severity of depression and anxiety. Change = (Month 6- Month 3).	Month 3 and Month 6
Secondary	Change from Baseline in Intestinal Function at Month 3	Intestinal function/mass is measured by citrulline plasma levels. Normal citrulline levels range from 20-50 umol/L. Higher levels indicate increased intestinal function.	Baseline and Month 3
Secondary	Change from Baseline in Intestinal Function from Month 3 to Month 6	Intestinal function/mass is measured by citrulline plasma levels. Normal citrulline levels range from 20-50 umol/L. Higher levels indicate increased intestinal function.	Month 3 and Month 6
Secondary	Number of Adverse Events per Treatment Group	Adverse events will be documented from baseline to the end of the study (6 months) in the Zinc supplementation and Zinc optimized diet group.	Baseline-Month 6